QurAlis’ Post

Embracing the uniqueness of every patient, and their rejection risk. Tutivia redefines kidney transplant patient assessments through personalized, patient-centric risk score results which deliver advancements over current clinical tools Including accurately predicting all types of early, acute rejection while avoiding false positives results for BKN. Tutivia has the potential to differentiate BK nephropathy from acute rejection. By providing patient-centric risk scores based on a select gene set that incorporates changes at the molecular level in biological pathways regulation, cellular metabolism and signaling, apoptosis, inflammation and immune activation, we are moving away from generalized one-size-fits-all approach, and instead, Verici Dx is offering tailored insight into an individual patient’s risk of acute rejection, ensuring that you have a powerful tool to aid in decision making for each of your kidney transplant patients. https://lnkd.in/ewzAaJzK Tutivia stands as a beacon of what’s possible when technology meets personalization. #PersonalizedEvenEarly #TutiviaDelivers#VRCI

Part 2 of our comprehensive AnaBios Research Highlights series continues to explore the invaluable insights shared by Dr. Rafal P. Witek, a prominent figure in the field of #hepatocytes. Through a meticulous examination of recent advancements, this video scrutinizes the multifaceted sources of variability inherent in in vitro experiments utilizing primary human hepatocytes. Moreover, it offers a critical appraisal of vendor practices, elucidating optimal #cryopreservation techniques and emphasizing the utmost importance of proper storage and handling protocols for hepatocytes. By delving into these intricacies, the video equips #researchers with indispensable knowledge to navigate the complexities of hepatocyte research. #earlyhumaninsights #drugdiscovery #liverresearch

https://lnkd.in/efF_P8N7 This article highlights the recent finding by the FDA on more than 60 identified genes with variants that can affect more than 190 drugs. The researchers estimated that about 80% of the study participants could have benefited until age 50 from genomic testing to identify potential pharmacological problems. This leads to the burning question, have you and/or loved ones experienced drug complications related to variants and aggravation of existing clinical symptoms?

https://lnkd.in/eqHDgx-Z Interesting and insightful article by National Center for Advancing Translational Sciences (NCATS) on a 2023 study on the efficacy of pharmacogenomics in patients funded by CTSA CCOS Center. This study illustrates the interface between genomic medicine and personalized medicine with a broad impact on clinical trials for patients with a rare mitochondrial disease. Zhan Ye, John Mayer, Richard A. Dart, Scott J. Hebbring Emili Leary Terrie Kitchner Murray Brilliant #mitochondrialdisease #mitochondria #personalizedmedicine #clinicaltrials #MELAS #LHONPlus

Liver disease affects millions worldwide. A new study, published in the journal Nature Metabolism, performed a retrospective analysis of 39 commonly used mouse and rat models to rank them according to their similarity to human metabolic dysfunction-associated steatotic liver disease (MASLD) to accelerate MASLD preclinical research. The ranking is based on a novel  unbiased ‘Human Proximity Score’ to rank mouse and rat models based on their metabolic, phenotypic and molecular relevance to help researchers choose the best models for their liver disease research. Find out more and explore the findings. https://lnkd.in/eb7J8Qxz #liverhealth #masld #metabolicdisease #diseasemodeling #litmus

Did you know that lipids can be indicative of disease pathology? They are imperative in cellular structure, bioenergetics and cell signaling. Characterizing lipid profiles is an important aspect of therapeutic development. Join us February 27th, 12pm EST where Natalie Daurio is using #timsTOF for understanding lipid dysregulation in metabolic diseases. #lipidomics #metabolomics #massspectrometry #massspec

I am excited to share my latest publication titled “Proteome profile of the cerebellum from α7 nicotinic acetylcholine receptor deficient mice”.👩🏼🔬🧠 #proteomics #massspectrometry #nicotinicreceptors

Some expert tips and advice from one of our resident experts. If you have any further questions please just let us know.

Designed to detect single nucleotide variants, small insertions or deletions, deletion-insertions, and copy number variants, our whole exome sequencing test provides answers that profoundly impact a patient’s medical journey. Learn more. https://bit.ly/3v4eGXA

Dr. Shoji Ichikawa presents “Utility of targeted RNA analysis in neurological disorders” at ACMG. If you weren’t able to attend, stay tuned next week for a blog featuring the takeaways of this informative presentation. #RNA #DNA #ACMG2024 #Classifi